Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any disease of the bone marrow.
Biomarker and diagnostic research for bone marrow disorder has been reported in the published literature.
6 clinical trials registered, 1 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07387354](https://clinicaltrials.gov/study/NCT07387354) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:00 AM UTC
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
PHASE1 |
Thomas Jefferson University |
UNKNOWN |
[NCT05732870](https://clinicaltrials.gov/study/NCT05732870) | OSTEOMICS: Identifying Regulators of Bone Homeostasis | — | Relation Therapeutics | RECRUITING |
[NCT07102849](https://clinicaltrials.gov/study/NCT07102849) | Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study | — | National Heart, Lung, and Blood Institute (NHLBI) | ENROLLING_BY_INVITATION |
[NCT06703138](https://clinicaltrials.gov/study/NCT06703138) | Role of Diffusion MRI in Differentiation of Various Bone Marrow Lesions | — | Assiut University | NOT_YET_RECRUITING |
[NCT03773393](https://clinicaltrials.gov/study/NCT03773393) | A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) | PHASE1 | Cellenkos, Inc. | ACTIVE_NOT_RECRUITING |
221 publications have been identified in PubMed for bone marrow disorder. Research spans Review / Meta-Analysis (42%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 91 | 42% |
Laboratory research | 56 | 26% |
Disease patterns and progression | 16 | 7% |
Patient case studies | 15 | 7% |
New treatment approaches | 15 | 7% |
Testing and diagnosis research | 11 | 5% |
Clinical study results | 9 | 4% |
Other research | 4 | 2% |
Pilcher WC (2026). [PMID: 41514053](https://pubmed.ncbi.nlm.nih.gov/41514053/). *Nat Cancer*. [Basic Science / Preclinical]
Park H (2026). [PMID: 41052483](https://pubmed.ncbi.nlm.nih.gov/41052483/). *Biomaterials*. [Basic Science / Preclinical]
Wang J (2026). [PMID: 41481427](https://pubmed.ncbi.nlm.nih.gov/41481427/). *Gut Microbes*. [Basic Science / Preclinical]
Maes J (2026). [PMID: 42265325](https://pubmed.ncbi.nlm.nih.gov/42265325/). *Eur J Nucl Med Mol Imaging*. [Other]
Schimmer RR (2026). [PMID: 41490322](https://pubmed.ncbi.nlm.nih.gov/41490322/). *Blood*. [Basic Science / Preclinical]
Diorio C (2026). [PMID: 41959729](https://pubmed.ncbi.nlm.nih.gov/41959729/). *Hemasphere*. [Epidemiology / Natural History]
Cheng S (2026). [PMID: 40543323](https://pubmed.ncbi.nlm.nih.gov/40543323/). *Biomaterials*. [Gene Therapy / Novel Therapeutics]
Morgenstern Y (2026). [PMID: 42122157](https://pubmed.ncbi.nlm.nih.gov/42122157/). *Cancers (Basel)*. [Basic Science / Preclinical]
Fakih H (2026). [PMID: 41695004](https://pubmed.ncbi.nlm.nih.gov/41695004/). *Cureus*. [Case Report / Case Series]
Shen Y (2026). [PMID: 41734765](https://pubmed.ncbi.nlm.nih.gov/41734765/). *Cell Stem Cell*. [Basic Science / Preclinical]